Author:
Naik Girish S.,Buchbinder Elizabeth I.,Cohen Justine V.,Manos Michael P.,Johnson Alistair E.W.,Bowling Peter,Aizer Ayal A.,Schoenfeld Jonathan D.,Lawrence Donald P.,Haq Rizwan,Hodi Frank Stephen,Sullivan Ryan J.,Ott Patrick A.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology,Immunology,Immunology and Allergy
Reference41 articles.
1. Demographics of brain metastasis;Johnson;Neurosurg Clin N Am,1996
2. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma;Sampson;J Neurosurg,1998
3. Determinants of outcome in melanoma patients with cerebral metastases;Fife;J Clin Oncol,2004
4. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial;Hodi;Lancet Oncol,2016
5. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献